



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

## Revision of Precautions Ceftriaxone sodium hydrate

August 2, 2018

## Non-proprietary name

Ceftriaxone sodium hydrate

## Safety measure

Precautions should be revised in the package insert.

The language concerning disturbed consciousness should be revised as follows in the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section (revised language is underlined):

## Neuropsychiatric symptoms:

Disturbed consciousness (loss of consciousness, decreased level of consciousness, etc.), convulsions, or involuntary movements (choreoathetosis, myoclonus, etc.) may occur. Patients should be carefully monitored, and if any abnormalities are observed, appropriate measures, such as discontinuing administration, should be taken. These symptoms have been reported in numerous patients with severe renal disorder.